/ 1 min read

Reed Smith advises Claret Capital Partners on €30 million structured financing for Carvolix

PARIS – Global law firm Reed Smith advised Claret Capital Partners on a structured debt financing transaction of up to €30 million for Carvolix (formerly Affluent Medical), a French medical technology company listed on Euronext Paris (ISIN: FR0013333077).

Carvolix announced on August 6, 2026, that it had entered into this transaction with funds managed by Claret Capital Partners, comprising senior secured convertible bonds and amortised bonds, together with warrants. The transaction is structured in four tranches of senior secured bonds: two convertible tranches of €10 million each, the first of which was immediately drawn down and the second of which is subject, among other conditions, to obtaining FDA 510(k) clearance for the Tavipilot robotic platform; and two amortised tranches of €5 million each.

The financing also includes warrants with a total value of €1,152,110. The maximum dilution resulting from the bonds and warrants combined is capped at 8.6% of the existing share capital if the bonds, totalling €30 million, are drawn in full. Bondholders benefit from first-ranking security over Carvolix’s bank accounts, a pledge over securities of certain of its subsidiaries, its intellectual property rights, and its business (fonds de commerce), as well as a receivable assignment agreement.

The Reed Smith team comprised Baptiste Gelpi (partner), Erij Akremi (associate), and Audrey Minnie (juriste) on the financing aspects and Guilain Hippolyte (partner) and Salomé Cloué (associate) on the corporate aspects.

About Reed Smith

Reed Smith is a dynamic international law firm dedicated to helping clients move their businesses forward. With an inclusive culture and innovative mindset, we deliver smarter, more creative legal services that drive better outcomes for our clients. Our deep industry knowledge, long-standing relationships and collaborative structure make us the go-to partner for complex disputes, transactions, and regulatory matters.

Related news

Related Insights